London, November 16
Advertisement
Britain’s medicines regulator has authorised the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the UK.
In a statement on Thursday, the Medicines and Healthcare Regulatory Agency (MHRA) said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel prize in 2020.
Advertisement
The agency approved the treatment for patients with sickle cell disease and thalassaemia who are over 12 years old. — AP
Advertisement
×
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Combo
Yearly
Monthly
Already a Member? Sign In Now
Advertisement
Advertisement
Advertisement